Alps Advisors Inc Krystal Biotech, Inc. Transaction History

Alps Advisors Inc

$17.2 Billion
Q2 2025

A detailed history of Alps Advisors Inc transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 17,462 shares of KRYS stock, worth $3.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

17,462

Previous 1,920 809.48%

Holding current value

$3.42 Million

Previous $346,000 593.64%

% of portfolio

0.01%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$123.36 - $181.0 $1.92 Million - $2.81 Million	15,542 Added 809.48%	17,462 $2.4 Million
Q1 2025 Apr 30, 2025	BUY	$142.64 - $194.44 $273,868 - $373,324	1,920 New	1,920 $346,000
Q3 2024 Nov 12, 2024	BUY	$174.7 - $213.66 $17,819 - $21,793	102 Added 0.46%	22,372 $4.07 Million
Q2 2024 Aug 13, 2024	BUY	$153.12 - $183.64 $3.41 Million - $4.09 Million	22,270 New	22,270 $4.09 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $41,667 - $50,004	384 Added 1.9%	20,620 $2.39 Million
Q2 2023 Aug 14, 2023	BUY	$78.48 - $130.32 $255,766 - $424,712	3,259 Added 19.2%	20,236 $2.38 Million
Q1 2023 May 10, 2023	SELL	$72.39 - $84.27 $33,806 - $39,354	-467 Reduced 2.68%	16,977 $1.36 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $214,865 - $271,899	3,403 Added 24.24%	17,444 $1.38 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $75,874 - $96,408	-1,170 Reduced 7.69%	14,041 $979,000
Q2 2022 Aug 11, 2022	SELL	$48.93 - $73.47 $523,648 - $786,275	-10,702 Reduced 41.3%	15,211 $999,000
Q1 2022 May 16, 2022	SELL	$51.99 - $72.11 $151,082 - $209,551	-2,906 Reduced 10.08%	25,913 $1.72 Million
Q4 2021 Feb 09, 2022	BUY	$39.81 - $88.24 $63,934 - $141,713	1,606 Added 5.9%	28,819 $2.02 Million
Q3 2021 Nov 15, 2021	SELL	$52.01 - $71.77 $105,476 - $145,549	-2,028 Reduced 6.94%	27,213 $1.42 Million
Q2 2021 Aug 11, 2021	SELL	$62.14 - $81.82 $398,503 - $524,711	-6,413 Reduced 17.99%	29,241 $1.99 Million
Q1 2021 May 07, 2021	BUY	$59.42 - $85.46 $6,595 - $9,486	111 Added 0.31%	35,654 $2.75 Million
Q4 2020 Feb 03, 2021	BUY	$40.64 - $61.38 $425,378 - $642,464	10,467 Added 41.74%	35,543 $2.13 Million
Q3 2020 Nov 04, 2020	BUY	$37.76 - $48.49 $51,240 - $65,800	1,357 Added 5.72%	25,076 $1.08 Million
Q2 2020 Aug 05, 2020	SELL	$37.03 - $60.0 $287,019 - $465,060	-7,751 Reduced 24.63%	23,719 $982,000
Q1 2020 May 06, 2020	SELL	$35.02 - $65.64 $117,877 - $220,944	-3,366 Reduced 9.66%	31,470 $1.36 Million
Q4 2019 Feb 07, 2020	BUY	$33.17 - $65.23 $11,543 - $22,700	348 Added 1.01%	34,836 $1.93 Million
Q3 2019 Nov 04, 2019	BUY	$34.72 - $51.3 $147,907 - $218,538	4,260 Added 14.09%	34,488 $1.2 Million
Q2 2019 Aug 07, 2019	SELL	$27.2 - $41.2 $125,745 - $190,467	-4,623 Reduced 13.27%	30,228 $1.22 Million
Q1 2019 May 01, 2019	BUY	$19.86 - $32.9 $29,929 - $49,580	1,507 Added 4.52%	34,851 $1.15 Million
Q4 2018 Feb 04, 2019	BUY	$15.03 - $25.38 $501,160 - $846,270	33,344 New	33,344 $693,000

Others Institutions Holding KRYS

# of Institutions

315

Shares Held

24.7M

Call Options Held

418K

Put Options Held

485K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $5.03B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Krystal Biotech, Inc. Transaction History